Agios Pharmaceuticals (AGIO) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Strategic vision and leadership

• Focused on developing transformative therapies for rare diseases, leveraging expertise in pyruvate kinase activation.

• Senior leadership team highlighted, with cross-functional expertise in medical, commercial, and financial operations.

• Achieved significant financial milestone with $1.1 billion in milestone payments, strengthening a pro forma balance sheet to $1.7 billion.

• Positioned to deploy capital effectively for future growth and expansion.

Product pipeline and clinical progress

• Mitapivat demonstrated compelling data across three hemolytic anemias: PK deficiency, thalassemia, and sickle cell disease.

• Two pivotal phase III studies in thalassemia read out positively; phase III RISE-UP study in sickle cell disease to complete enrollment by year-end.

• Tebapivat (formerly AG-946) received orphan drug designation and initiated phase IIB study in low-risk MDS.

• Plans to file with regulators for thalassemia based on combined ENERGIZE and ENERGIZE-T studies by year-end.

Mechanism of action and therapeutic impact

• Pyruvate kinase activation enhances red blood cell energy, improving survival and function in rare anemias.

• Mitapivat shown to improve hemoglobin, reduce transfusions, and enhance quality of life, including fatigue reduction.

• Positive patient-reported outcomes and strong treatment persistency observed in real-world PK deficiency use.